Stock NRIX NURIX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/06/2024 BST 		5-day change 1st Jan Change
20.46 USD -1.63% Intraday chart for Nurix Therapeutics, Inc. +10.95% +98.26%
06-20 Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing MT
06-18 HC Wainwright Raises Price Target on Nurix Therapeutics to $26 From $19, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing
MT
HC Wainwright Raises Price Target on Nurix Therapeutics to $26 From $19, Maintains Buy Rating
MT
JPMorgan Adjusts Price Target on Nurix Therapeutics to $31 From $30, Maintains Overweight Rating
MT
Sector Update: Health Care Stocks Decline Premarket Monday
MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell
MT
Sector Update: Health Care
MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of More Economic Data
MT
Top Premarket Gainers
MT
Nurix Therapeutics Says Patients Respond Well to Potential Non-Hodgkin Lymphoma Treatment in Phase 1 Trial
MT
Transcript : Nurix Therapeutics, Inc. - Special Call
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
AQ
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress
CI
Nurix Therapeutics Files Mixed Shelf Registration
MT
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
CI
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
CI
Certain Pre-Funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
CI
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
CI
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
AQ
Transcript : Nurix Therapeutics, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 05:30 PM
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRIX Stock
  4. News Nurix Therapeutics, Inc.